Press "Enter" to skip to content

American Cancer Society urges PSA screening for men in 50s and 60s

The American Cancer Society announced on November 12, 2026 that it is revising its prostate cancer screening guidance to make testing a proactive recommendation for most men. In an interview with The Conversation, Dr. Andrew Wolf of the University of Virginia, a lead author of the updated guidance, explained the new age‑specific recommendations and the evidence that prompted the shift.

Key changes to screening recommendations

For men at average risk, the society now advises a prostate‑specific antigen (PSA) blood test every two years beginning at age 50 and continuing until age 69. PSA, a protein produced by prostate cells, can rise in the presence of cancer or other prostate conditions.

Men identified as higher risk – including Black men and those with a strong family history of prostate cancer – should be screened annually from age 45 through 69. A “strong” family history is defined as a first‑degree relative diagnosed before age 65, or multiple relatives diagnosed at any age. Men with a single relative diagnosed at age 65 or older are advised to have PSA testing every two years starting at 45.

For those aged 70 to 74, the guidance calls for a shared decision‑making conversation with a health‑care provider, weighing personal preferences, overall health, and life expectancy. Men older than 74 are advised against routine screening, as the potential harms – such as invasive follow‑up procedures and overtreatment – are thought to outweigh any benefit.

The new guidelines also recommend against using the digital rectal exam (DRE) as a primary screening tool, citing lower effectiveness compared with PSA testing. DRE may still be employed when evaluating an elevated PSA or related symptoms.

Evidence driving the update

Over the past decade, accumulating data have clarified the advantages of PSA screening. Researchers now believe the test’s ability to lower prostate‑cancer mortality and reduce metastatic disease is greater than earlier estimates. At the same time, advances in diagnostic pathways have lessened the frequency of false‑positive results and the treatment of indolent tumors that would not have caused harm.

Historical controversy stemmed from two large 2009 trials. A U.S. study showed no mortality benefit, but later analysis revealed that nearly 90 percent of men in the control arm received PSA testing anyway, undermining the comparison. In contrast, the European trial adhered more closely to its design, and long‑term follow‑up demonstrated a 13 percent reduction in prostate‑cancer deaths, with roughly 500 men needing to be screened to prevent one death. Dr. Wolf noted that this number is comparable to the screening yield of mammography for breast cancer.

These findings, combined with improved management of abnormal results, gave the ACS confidence to move from a “talk with your doctor” stance to an active recommendation for most men.

Considerations and patient concerns

Dr. Wolf acknowledged that some men may hesitate because screening can lead to a prostate biopsy, which can be uncomfortable and occasionally cause bleeding or infection. Detecting a low‑grade tumor may also trigger active surveillance protocols involving periodic biopsies and imaging, which some find anxiety‑provoking.

Potential treatment side effects – including sexual, urinary and bowel dysfunction – are another source of reluctance. Nonetheless, Dr. Wolf emphasized that foregoing screening eliminates the chance to catch cancer at a stage when cure rates are highest.

Insurance coverage for the recommended PSA tests is expected to be broad, though patients might incur out‑of‑pocket costs for additional diagnostic procedures if a PSA level is elevated.

The new ACS recommendations differ from the U.S. Preventive Services Task Force (USPSTF), which in its 2018 update advised against routine screening unless patients explicitly request it. The USPSTF is currently reviewing its stance, and future alignment with the ACS is possible. Both agencies agree that men should be fully informed about the benefits, risks, and limitations of screening before deciding.

Overall, the revised guidance aims to balance early detection with minimized harm, targeting men most likely to benefit while providing clear pathways for shared decision‑making in older age groups.